Trench Fever Treatment Market Segmentation:
Type Segment Analysis
The Doxycycline segment is expected to garner 38.3% share owing to its superior efficacy as 1st line therapy. The CDC also mentions doxycycline as the preferred drug for body louse-borne infections. In more than 91% of the Medicaid-covered Trench Fever cases, doxycycline has been given. Additionally, the medicine has been listed as a crucial drug for the treatment of the louse-borne infections. Also, there has been a surge in the low-cost treatment for treating larger populations. The widespread adoption by hospitals and shelters is bolstering the sales of the manufacturer.
Diagnosis Method Segment Analysis
The PCR-based segment is projected to register 36% of the share as it is considered to be the gold standard for accurate detection. The PCR-based detection also lowers the chances of false negatives crucial in the homeless population areas with extremely high exposure risks. Also, the turnaround time for such testing is faster in comparison with the conventional methods. It also enables same-day patient triage in the shelters and mobile clinics. Various governments are investing in the PCR-based mass screening for the high-risk areas.
Our in-depth analysis of the global trench fever treatment market includes the following segments:
| Segment | Subsegment |
|
Type |
|
|
Distribution Channel |
|
|
End user |
|
|
Diagnosis Method |
|
